Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 2, Issue 11, pp. 1048-1063
PubMed
Published By
Print ISSN
Online ISSN
History
- Received December 21, 2011
- Revision received July 1, 2012
- Accepted August 8, 2012
- Published first August 22, 2012.
Article Versions
- Previous version (August 22, 2012 - 05:26).
- Previous version (October 2, 2012 - 07:43).
- Previous version (October 23, 2012 - 13:02).
- You are viewing the most recent version of this article.
Copyright & Usage
©2012 American Association for Cancer Research.
Author Information
- Ashish Juvekar1,
- Laura N. Burga1,
- Hai Hu1,
- Elaine P. Lunsford1,
- Yasir H. Ibrahim5,
- Judith Balmañà5,
- Anbazhagan Rajendran1,
- Antonella Papa2,
- Katherine Spencer1,
- Costas A. Lyssiotis3,
- Caterina Nardella2,
- Pier Paolo Pandolfi2,
- José Baselga4,5,
- Ralph Scully1,
- John M. Asara3,
- Lewis C. Cantley3 and
- Gerburg M. Wulf1
- Authors' Affiliations: Divisions of 1Hematology and Oncology,2Cancer Genetics, and 3Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School; 4Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts; and5Medical Oncology Department, University Hospital Vall d'Hebron, Paseo Vall d'Hebron, Barcelona, Spain
- Corresponding Author:
Gerburg M. Wulf, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. Phone: 617-667-1910; Fax: 617-667-1960; E-mail: gwulf{at}bidmc.harvard.edu
L.N. Burga and H. Hu contributed equally to this work.
November 2012
Volume 2, Issue 11
Volume 2, Issue 11
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Jump to section
Advertisement